The second leading cause of cancer death in American men is prostate cancer. (Lung cancer is first.) In 2002, doctors told an estimated 189,000 men that they have the potentially fatal disease. In an effort to lower these numbers in the future, researchers are investigating many possible markers for prostate cancer. These markers may one day help identify men at higher risk.

For example, a gene called AMACR (x-methylacyl-CoA racemase) appears to trigger production of a specific protein found only in cancer cells, and has been identified as a potential prostate cancer marker by several groups of researchers. The findings suggest that AMACR could eventually help pinpoint early prostate cancer and enhance diagnostic accuracy. In theory, a blood test for the gene could reduce the need for needle biopsies of the prostate.

"Since AMACR enzymatic activity is not found in most normal tissues, it could be used to…develop molecular probes for noninvasive detection of prostate cancer," says June Luo, Ph.D., lead author of a Johns Hopkins study.

The protein produced by AMACR helps the body metabolize certain fatty acids, such as those found in dairy products and beef. Researchers caution that the link, if any, between an overexpression of AMACR and a man's diet warrants further study.

In the meantime, the medical community is deeply divided over the issue of current screening for prostate cancer. At this time, there is no evidence that detecting prostate cancer early saves lives, and it is possible that the harm caused by subsequent procedures such as surgery, radiation, hormonal therapy or chemotherapy may outweigh any possible benefit.